| Business Summary | | Neose
Technologies,
Inc.
develops
proprietary
technologies
for
the
synthesis
and
manufacture
of
complex
carbohydrates.
The
Company's
enzymatic
glycosylation
technology
platform
makes
feasible
the
synthesis
and
modification
of
a
wide
range
of
complex
carbohydrates,
which
are
chains
of
simple
sugar
molecules
that
can
be
joined
together
in
many
different
combinations.
The
Company's
methods
can
produce
complex
carbohydrates
that
are
attached
to
proteins,
as
in
recombinant
therapeutic
glycoproteins,
are
attached
to
lipids,
as
in
therapeutic
cancer
vaccines
or
are
solely
carbohydrates,
as
found
in
human
breast
milk.
The
Company's
technology
is
also
capable
of
correcting
or
completing
the
human
carbohydrate
patterns
on
glycoproteins,
potentially
resulting
in
improved
pharmacokinetic
profile,
strengthened
patent
claims
and
manufacturing
efficiencies. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | NTEC
is
focused
on
the
enzymatic
synthesis
of
complex
carbohydrates,
and
discovers
and
develops
complex
carbohydrates
for
nutritional,
pharmaceutical,
consumer
and
industrial
uses.
For
the
six
months
ended
6/01,
revenues
fell
84%
to
$604
thousand.
Net
loss
totaled
$8.5
million,
up
from
$3.9
million.
Revenues
reflect
the
absence
of
payments
received
from
agreements
with
Bristol-Myers.
Net
loss
also
reflects
higher
S/G/A
expenses
due
to
additional
personnel. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Stephen Roth, Ph.D., 58 Chairman,
CEO | $389K | -- | P. Sherrill Neff, 49 Pres,
COO, Chief Financial Officer, Director | 381K | -- | Eric Sichel, M.D., 42 VP,
Bus. Strategy and Corp. Communications | -- | -- | David Zopf, M.D., 58 VP
of Drug Devel. | 239K | $148K | Edward McGuire, Ph.D., 63 VP-R&D | 204K | 541K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|